Stock NXGL NEXGEL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

NEXGEL, Inc. Share Price

Equities

NXGL

US65344E1073

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 21:30:01 14/05/2024 BST 		5-day change 1st Jan Change
2.2 USD -2.00% Intraday chart for NEXGEL, Inc. -0.45% +3.29%
05-13 Transcript : NEXGEL, Inc., Q1 2024 Earnings Call, May 13, 2024
05-13 Earnings Flash (NXGL) NEXGEL Reports Q1 Revenue $1.3M, vs. Street Est of $1.2M MT

Financials

Sales 2024 * 6.17M 490M Sales 2025 * 9.32M 740M Capitalization 13.7M 1.09B
Net income 2024 * -3M -238M Net income 2025 * - 0 EV / Sales 2024 * 2.22 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.47 x
P/E ratio 2024 *
-4 x
P/E ratio 2025 *
-73.3 x
Employees 19
Yield 2024 *
-
Yield 2025 *
-
Free-Float 77.18%
More Fundamentals * Assessed data

Chart NEXGEL, Inc.

Dynamic Chart

Latest news about NEXGEL, Inc.

Transcript : NEXGEL, Inc., Q1 2024 Earnings Call, May 13, 2024
Earnings Flash (NXGL) NEXGEL Reports Q1 Revenue $1.3M, vs. Street Est of $1.2M MT
NEXGEL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : NEXGEL, Inc., Q4 2023 Earnings Call, Apr 01, 2024
Earnings Flash (NXGL) NEXGEL Posts Q4 Revenue $1.1M MT
NEXGEL, Inc. Provides Revenue Guidance for the First Quarter of 2023 CI
NEXGEL, Inc. Announces Intention of Miranda J. Toledano to Resign as a Member of the Board of Directors, Effective as of March 31, 2024 CI
Top Premarket Decliners MT
Nexgel Subsidiary, Cg Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024 CI
NEXGEL, Inc. Announces Resignation of David Stefansky as Member of the Board of Directors CI
Nexgel Enters Deal With Stada Arzneimittel to Distribute OTC Products Across North America MT
NEXGEL, Inc. Announces Partnership with STADA Arzneimittel AG to Distribute and Commercialize Consumer Health OTC Products in North America CI
NEXGEL, Inc. acquired Kenkoderm from Olympus Trading Company, LLC for $1.1 million. CI
Tranche Update on NEXGEL, Inc.'s Equity Buyback Plan announced on December 7, 2022. CI
NEXGEL, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
More news

Latest transcript on NEXGEL, Inc.

Logo NEXGEL, Inc.
NEXGEL, Inc., Q1 2024 Earnings Call, May 13, 2024
More transcripts

Press releases NEXGEL, Inc.

NEXGEL Reports First Quarter 2024 Revenue of $1.27 Million, an Increase of 104% Year-Over-Year AQ
NEXGEL to Report First Quarter 2024 Financial Results on May 13th AQ
NEXGEL to Present at the Aegis Capital Virtual Conference on May 9, 2024 AQ
NEXGEL to Present at the Planet MicroCap Showcase: VEGAS 2024, May 1 & 2, 2024 AQ
NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year AQ
More press releases

Quotes and Performance

1 day-2.00%
1 week-0.45%
Current month+3.77%
1 month+0.92%
3 months+4.27%
6 months+22.91%
Current year+3.29%
More quotes

Highs and lows

1 week
2.20
Extreme 2.197
2.35
1 month
1.98
Extreme 1.98
2.36
Current year
1.98
Extreme 1.98
3.14
1 year
1.46
Extreme 1.46
3.14
3 years
1.09
Extreme 1.09
4.66
5 years
1.09
Extreme 1.09
4.66
10 years
1.09
Extreme 1.09
4.66
More quotes

Managers and Directors - NEXGEL, Inc.

Managers TitleAgeSince
Adam Levy CEO
 Chief Executive Officer 61 09/09/19
Adam Drapczuk DFI
 Director of Finance/CFO 48 31/05/21
Gregory J. Robb COO
 Chief Operating Officer - -
Members of the board TitleAgeSince
Scott Henry BRD
 Director/Board Member 53 15/01/23
Nachum Stein BRD
 Director/Board Member 75 09/09/19
Jerome Zeldis BRD
 Director/Board Member 74 31/03/20
More insiders

Quotes

Date Price Change Volume
14/05/24 2.2 -2.00% 18,001
13/05/24 2.245 +2.18% 12,565
10/05/24 2.197 -1.48% 8,714
09/05/24 2.23 +0.90% 7,104
08/05/24 2.21 0.00% 4,573

Delayed Quote Nasdaq, May 14, 2024 at 09:30 pm

More quotes

Company Profile

NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including ultra-gentle, high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CG labs segment comprises the CG Converting and Packaging, LLC used for the Company’s converting and packaging business, which is based in Granbury, Texas. All of its gel products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Its hydrogel consumer products are marketed under the brand names MedaGel and LumaGel Beauty.
Sector
Pharmaceuticals
Calendar
17/06/2024 - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Ratings for NEXGEL, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.2 USD
Average target price
6 USD
Spread / Average Target
+172.73%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
NEXGEL, INC. Stock NEXGEL, Inc.
+3.29% 13.98M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+31.06% 682B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.35% 586B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.42% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.02% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.27% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.53% 240B
NOVARTIS AG Stock Novartis AG
+10.16% 209B
ROCHE HOLDING AG Stock Roche Holding AG
-8.14% 203B
AMGEN INC. Stock Amgen Inc.
+8.12% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. NXGL Stock